Future Microbiology
Routine detection and identification of bacterial infections is traditionally done by inoculation of patient sample material on culture media and isolation and subsequent phenotypic characterization of growing pathogenic bacteria. Molecular detection has largely been restricted to agents that cannot be isolated by standard axenic culture media (e.g., Coxiella burnetii) and slow-growing organisms such as Legionella pneumophila and Mycobacterium tuberculosis. Nonmolecular culture-independent methods such as blood, cerebrospinal and urine antigen tests are available for a number of specific bacteria and can be used when culture is negative, for instance after administration of antibiotics to the patient. For the majority of bacterial infections, however, it is impossible to establish the causative agent if culture fails to produce specific pathogens. Availability of generally applicable culture-independent detection and identification methods that can be used on a routine basis are clearly warranted. PCR of bacterial ribosomal genes with subsequent DNA sequencing of the PCR product offers such an opportunity.
Background
Approximately 30 years ago, analysis of DNA sequences was introduced as a tool to investigate the evolution and relatedness of bacteria [1] . Because of a constant slow random substitution of bases in parts of the genes encoding rRNA, closely related bacteria have very similar DNA sequences whereas remotely related bacteria vary more from each other in their DNA sequence. Conserved sequences flank these varying sequences [2] . The conserved sequences can be used as targets for primers in PCR, allowing amplification of DNA fragments containing the varied sequences. The DNA sequence of the amplified fragment can be used to identify the species of the bacterium by comparing it with DNA sequences of previously identified bacteria in public or commercial databases [3, 4, 101, 102] . By use of modern technology large numbers of samples can be processed on a routine basis within a few days [5] [6] [7] .
Identification of bacterial isolates
Ribosomal DNA sequencing is widely used to identify clinically derived bacterial isolates [4, 8] . Mostly, final identity is obtained by DNA sequencing of the first 440-520 bp of the 16S rRNA gene [6, 9, 10] . If definitive identification is not obtained by partial DNA sequencing of the 16S rRNA gene, or if the results are expected to be reported in scientific publications, full-length DNA sequencing, which is a little more laborious, should be applied. The 16S rRNA gene is a preferable target for identification because databases based on DNA sequences from the 16S rRNA gene are large, rapidly growing and are constantly updated with data on newly described species [5, 11] . Correlating bacterial classification, especially of newly described or rarely found species, with clinical presentation is an ongoing [12] . Ribosomal DNA sequencing has also established the pathogenic potential of bacteria that have not previously, or only rarely, been regarded as true agents of disease [13] [14] [15] [16] [17] . Partial or full-length DNA sequencing of the 16S rRNA gene may correct clinically important erroneous identifications based on traditional methods [18] .
In a small number of cases, ribosomal DNA sequencing does not allow differentiation between a few closely related species, and a limited number of carefully selected additional biochemical reactions can then be applied for definite identification [9] . Some species, including some Enterobacteriaceae and some non hemolytic streptococci have very similar DNA 16S rRNA gene sequences [19] , and other targets may be more suitable for identification. Thus, for the latter group of bacteria, it has been found that DNA sequencing of the 16S-23S intergenic spacer region and of part of the gdh gene in combination enables identification [20] .
Direct detection & identification of bacteria in human infections
Based on the success of identifying isolated bacteria by ribosomal DNA sequencing it appeared as an obvious option to apply the technique for direct detection and identification of bacteria in patient material without initial isolation by culture. For direct application of ribosomal DNA sequencing, technical modifications must be made, taking into consideration aspects of sensibility, contamination risk, multibacterial infections and other factors that are not problematic when sequencing DNA from bacteria isolated in culture
The value of supplementing culture with ribosomal PCR and DNA sequencing depends on the selection of patient material. One study found PCR positive in 73 out of 536 samples from various infectious foci, 30 of which were positive in PCR only [21] . In that study the etiologic agent was established by ribosomal PCR and DNA sequencing in 11 out of 459 patients without a conclusive culture result.
Confirmation of bacterial identifications in culture-negative infections
Most bacterial identifications obtained by ribosomal PCR and DNA sequencing of culture-negative samples in our laboratory are not surprising when considering the actual clinical situation. Occasionally, DNA sequencing has resulted in identification of bacteria that were absolutely unexpected. Thus, ribosomal PCR and DNA sequencing may identify unusual bacteria or well-known bacteria in unusual infectious foci. In both situations it may be necessary to confirm the identity by other methods. Confirmation may be obtained by culturing the bacterium identified by ribosomal DNA sequencing, either from another focus [22] or at another time point [23] . Adjusting culture conditions may also sometimes allow the infecting bacterium to grow. The anaerobic bacteria Kingella kingae, Actinobaculum schaalii, Mycoplasma spp. and Coxiella burnetii have been cultured from originally culturenegative patient material when provided with specific culture conditions after identification by ribosomal DNA sequencing.
If culture cannot confirm identification obtained by DNA sequencing, antigen tests may be useful. Unexpected findings in DNA from Streptococcus pneumoniae in soft tissue infections and osteoarticular infections have been confirmed and the serotype determined by testing of pneumococcal capsular antigen [24] in the urine of the patients [ 
Serologic responses may develop in long-lasting bacterial infections. For a number of noncultivable or difficult-to-grow bacteria, such as C. burnetii, Bartonella spp. and others, diagnosis depended on demonstration of high or increasing titers of antibodies when molecular methods were not yet available. Such assays are still useful and may confirm identification made by ribosomal DNA sequencing.
When nonmolecular biological confirmatory analyses are not available, demonstration of species-specific genes or -more generally usable -sequencing of alternative genes can be applied. We have previously used DNA sequencing of part of the 23S rRNA gene for primary identification of bacteria in clinical sample material [25] and have now started to successfully use this gene for confirmation of results from sequencing of the 16S rRNA gene when no other methods are available 
Clinical settings
A number of studies have documented the value of ribosomal PCR with subsequent DNA sequencing of PCR products in various clinical situations, including infections of the central nervous system [26] [27] [28] [29] [30] [31] , cardiac valves [32] [33] [34] [35] [36] , and joints and bones [25, 37] . Other studies have focused on the usefulness in selected patient groups such as children [38] .
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It is important to understand that PCR for bacteria is less sensitive than culture. Only one viable colony-forming unit is needed to obtain a positive culture result. Isolation of DNA for PCR is usually done from small volumes, typically 200 µl to 1 ml. As a standard, only a small fraction of the purified DNA from a clinical sample is used for the PCR, further reducing the chance of detecting DNA sequences present in low concentrations. Use of larger starting volumes and enrichment of bacterial DNA relative to human DNA using Looxster ® (SIRS laboratory, Jena, Germany), InfectoPrep ® (AppliChem, Darmstadt, Germany), MolYsis ® (Molzym, Bremen, Germany) and others may improve sensitivity [39] [40] [41] . Other technical solutions for increasing sensitivity may also be applied. Because of the limited sensitivity of PCR, the possibility of PCR-inhibiting factors in the sample and the presence of bacteria without DNA sequences targeted by the primers used for PCR, a negative result does not necessarily rule out bacterial infection. Interpretation of negative results must be performed with respect to the individual clinical status in each case.
As for other PCR analyses, the interpretation of detection of DNA from bacteria should always be done in relation to the individual clinical situation. Bacterial DNA from past infections may persist for prolonged periods of time [42] , which may lead to false-positive diagnoses. In contrast to PCR analysis for specific agents, PCR for bacteria in general can be influenced by contamination by any bacterium [43] . Therefore, these analyses are particularly sensitive to contamination before and during analyses. Standard sterile and pyrogen-free water and transport media intended for culture are not necessarily free of bacterial DNA. Even reagents for PCR, including most polymerase enzymes, may be contaminated with bacterial DNA. The precautions taken by most diagnostic PCR laboratories against contamination with PCR products are even more important when analyzing ribosomal DNA. These include separation of laboratories doing pre-and post-PCR procedures (preferably separate buildings) and restricted access to these rooms. Appropriate negative controls must be included to exclude contamination during processing. Because of the high risk of contamination it is fundamentally important that the clinical relevance of each bacterium detected and identified by DNA sequencing is critically evaluated by trained clinical microbiologists or infectious disease specialists.
To identify individual bacteria in mixed infections, the individual PCR products must first be separated. This may be done by cloning, but this is time consuming and expensive and thus not suited for large-scale routine ana lysis of clinical sample material. PCR products of similar size with different DNA sequences may be separated by electrophoresis systems [44] [45] [46] or by high performance liquid chromatography [47, 48] . Compared with the more widely used denaturating gradient gel electrophoresis, temperature gradient gel electrophoresis is fast, easy and inexpensive. Little has been published on the separation of microbial ribosomal gene PCR products by temperature gradient gel electrophoresis, but data on its use in environmental bacterial samples have been published [49] . Separated PCR products are easily restricted and eluted from the gels and processed further for DNA sequencing. Recently it has become possible to directly identify individual bacteria in mixed sequencing chromatograms of multibacterial infections. Chromatograms containing 16S rRNA PCR products from several bacteria are analyzed by a computerized algorithm [50] . The system works well and provides almost immediate clinically important information on bacteria in human infections [51, 52] .
Detection and identification of ribosomal DNA is considered a technique that is to be used in material from sterile sites only. Nevertheless, when a disease-causing bacterium is quantitatively strongly dominant in a focus with concomitant normal bacterial flora, it may be possible to detect it by direct PCR and DNA sequencing. In a confirmed case of chancroid, DNA from Haemophilus ducreyi was detected simply by amplifying and sequencing ribosomal DNA from the genital ulcer [53] .
Mass spectrometry is a new and very promising tool for the identification of isolated bacteria. It is very fast, easy to perform, relatively inexpensive and reasonably reliable [54] . Thus, it is suitable for large-scale routine identification of most bacteria isolated in the clinical laboratory and may be seen as an alternative to DNA sequencing. However, compared with DNA sequencing mass spectrometry still has some limitations: the databases available are still somewhat limited, and rare and recently described species are not always correctly identified. Also, even when DNA sequencing fails to correctly identify the species, it will often either suggest the correct genus or closely related species as alternatives. Alternatives to best match obtained by mass spectrometry are often not related to the particular species. Finally, mass future science group Review Kemp, Jensen, Dargis & Christensen spectrometry can only be performed on growing bacteria, whereas PCR and DNA sequencing offers a unique possibility to identify noncultivable or killed bacteria. The two methods should be seen as supplementary to each other, each with advantages in different situations.
Organization
Ribosomal PCR and DNA sequencing cannot replace culture, but it may provide important information in culture-negative cases of bacterial infections. To be of any value as a clinically relevant diagnostic method, processing time from when a sample is received in the laboratory to when a final conclusive result is available should be as short as possible. In order to prevent delay, the analyses should be performed every or every other day, depending on the number of samples received. Also, to speed up the process the clinician can order a combination of analyses so that a sample is immediately analyzed by ribosomal PCR and DNA sequencing if a culture turns out negative.
PCR and DNA sequencing is not a low-cost method, but costs may be reduced greatly by organizing the work in a rational manner. Most expenses are related to manual handling of samples and as handling of a large number of samples only takes a little more time than handling of a few samples, the per-sample price is markedly reduced when large numbers of samples are analyzed simultaneously.
Equipment for DNA sequencing and knowledge of how to use it is increasingly available to clinical microbiological laboratories. Alternatively, DNA sequencing of PCR products can be done fast and inexpensively by external partners. As with microbiological findings obtained by other techniques, correct interpretation of results obtained by ribosomal PCR and DNA sequencing depends on a combination of clinical and laboratory experience, which can only be obtained and maintained by frequent practice. Diagnostic PCR and DNA sequencing should always follow strict protocols and include appropriate controls. Even when doing so there are many steps in the process that requires experience. Validating chromatograms and checking them for mixed infections, editing and blasting sequences and evaluating and relating the result to the clinical disease manifestation are all procedures that require experience on top of strict laboratory performance. Thus, to obtain fast, affordable and reliable results it is essential that a sufficient number of samples are analyzed by each individual laboratory offering the test.
Conclusion
Routine use of ribosomal DNA sequencing fills an enormous gap in the microbiological laboratory diagnosis of bacterial infections. High costs and long processing times have been factors that have hindered more widespread use. Constant technical improvements and largescale analyses now make it possible to use the technique as a clinically relevant, routine tool at a reasonable price. Use of DNA-free reagents and semi-selective enrichment of bacterial DNA are two of several ways to improve sensitivity. Physical separation of PCR products with different DNA sequences or new methods for analyzing sequencing chromatograms allow determination of individual bacteria in multibacterial infections. All these improvements have made ribosomal PCR and DNA sequencing a more clinically relevant diagnostic procedure.
Future perspective
During recent years ribosomal PCR and DNA sequencing has developed from an expensive and exclusive test used only in very selected cases to a standard analysis generally applied on a routine basis to determine bacteria in culture-negative infections. In the future this development will continue and the method will become even more widespread. In addition to detecting classical pathogens after antibiotic treatment the method has proven its value by identifying organisms with special requirements for growth in vitro as infectious agents in humans. Furthermore, ribosomal PCR and DNA sequencing has already revealed a number of bacteria previously regarded as apathogenic as true causes of disease. The number of such new pathogens will undoubtedly continue to increase as the method becomes more widespread. Finally, ribosomal DNA sequencing may reveal the existence of some bacterial infections in geographic locations where they were not previously known. Bartonella quintana [ Jensen et al., Manuscript in preparation] and C. burnetii [55] were both recently found as agents of infective endocarditis in Greenland, which was hitherto regarded as an area free of bartonellosis and Q fever. Thus, the method will not only be valuable in the diagnosis of infections in single patients; it will also contribute to broadening our understanding of the nature of infectious diseases.
Currently there is a trend in bacteriology that increasingly more species are routinely characterized beyond the identification level. Clinically relevant functional characteristics including virulence factors and antibiotic future science group Routine ribosomal PCR & DNA sequencing for detection & identification of bacteria Review resistance markers are increasingly analyzed by molecular techniques, and subspecies are typed for epidemiological uses. Combining molecular identification and molecular characterization of uncultured bacteria should be expected to begin to take place in the very near future.
Most probably, in 5-10 years from now, ribosomal PCR and DNA sequencing will be as common and as integrated a part of clinical laboratory diagnostics as culture is today.
Executive summary

Identification of bacteria
n DNA sequencing is increasingly used for identification of bacteria, including bacteria that can not be cultivated in vitro. n Many bacteria can be identified by DNA sequencing of the first 500 bp of the 16S rRNA gene, but some groups including some enteric Gram-negative rods and non-hemolytic streptococci do not show sufficient variation for discrimination between species.
Confirmation of bacterial identifications
n Rare and unexpected findings may be confirmed by culture, antigen detection or serologic response. Specific nucleic acid assays or DNA sequencing of alternative targets may also be used for confirmation.
Clinical settings
n Ribosomal DNA sequencing is an obvious diagnostic option in culture-negative acute severe infections, as well as in long-lasting infections of high personal and economic importance, such as orthopedic infections.
Technical considerations
n Assays for ribosomal PCR and DNA sequencing from clinical sample material constantly undergo technical improvement. n Contamination before and during processing in the laboratory is still of major concern and results must be interpreted with caution. n Multibacterial infections have been a major challenge. New techniques are available for separation of PCR products and analyses of chromatograms from mixed infections.
Organization n DNA sequencing of ribosomal genes can be organized to give fast and inexpensive results, which is necessary to be of clinical relevance. n A minimum number of samples should be processed by individual laboratories in order to maintain expertise and keep costs at a low level.
Future perspective
n Diagnosing bacterial infections by ribosomal DNA sequencing should become an integrated part of clinical microbiology and routine in culture-negative infections.
n In the future, identification of bacteria in culture-negative infections may be supplemented with relevant molecular characterization, including analyses of virulence markers and of genes for antibiotic resistance.
future science group The discovery of new bacterial species as agents of human infection is an important result of using ribosomal DNA sequencing for bacterial identification.
